{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:59:21Z","timestamp":1785455961582,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104476"],"award-info":[{"award-number":["82104476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jval.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:55:09Z","timestamp":1771952109000},"page":"1385-1394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Yamin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2026.02.004_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.jval.2026.02.004_bib3","article-title":"How I treat metastatic triple-negative breast cancer","volume":"4","author":"Caparica","year":"2019","journal-title":"ESMO Open"},{"issue":"25","key":"10.1016\/j.jval.2026.02.004_bib4","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody-drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.jval.2026.02.004_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer","volume":"68","author":"Lang","year":"2023","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.jval.2026.02.004_bib7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.jval.2026.02.004_bib8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2026.02.004_bib11","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.clbc.2024.04.010","article-title":"Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China","volume":"24","author":"Wang","year":"2024","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12962-024-00539-y","article-title":"Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis","volume":"22","author":"Wu","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2026.02.004_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104550","article-title":"Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China","volume":"83","author":"Shu","year":"2025","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.jval.2026.02.004_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Dec Mak"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s41669-023-00455-6","article-title":"The acceptance of indirect treatment comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain","volume":"8","author":"Macabeo","year":"2024","journal-title":"Pharmacoecon Open"},{"issue":"15","key":"10.1016\/j.jval.2026.02.004_bib16","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized Phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2026.02.004_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.jval.2026.02.004_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jval.2026.02.004_bib19","first-page":"130","article-title":"Simple tool implementing Bucher\u2019s method for indirect treatment comparisons in meta-analyses. Evid Based Med","volume":"30","author":"Tingle","year":"2025","journal-title":"BMJ"},{"issue":"3-4","key":"10.1016\/j.jval.2026.02.004_bib20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res Synth Methods"},{"issue":"7","key":"10.1016\/j.jval.2026.02.004_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jval.2020.03.010","article-title":"Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis","volume":"23","author":"Wiksten","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.02.004_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091961","article-title":"Selection of indirect treatment comparisons for health technology assessments: a practical guide for health economics and outcomes research scientists and clinicians","volume":"15","author":"Guo","year":"2025","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jval.2026.02.004_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155389","article-title":"Nivolumab versus cabozantinib: comparing Overall Survival in Metastatic Renal Cell Carcinoma","volume":"11","author":"Wiecek","year":"2016","journal-title":"PLOS One"},{"issue":"8","key":"10.1016\/j.jval.2026.02.004_bib24","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0004","article-title":"Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma","volume":"12","author":"Petersohn","year":"2023","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jval.2026.02.004_bib25","series-title":"Multivariate Meta-Analysis of Summary Data for Combining Treatment Effects on Correlated Outcomes and Evaluating Surrogate Endpoints. Technical Support Documents","author":"Bujkiewicz","year":"2019"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12874-022-01746-y","article-title":"A bayesian approach to model the underlying predictors of early recurrence and postoperative death in patients with colorectal Cancer","volume":"22","author":"Mahmoudi","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jval.2026.02.004_bib27","series-title":"NICE Decision Support Unit Technical Support Document 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review","author":"Woods","year":"2017"},{"key":"10.1016\/j.jval.2026.02.004_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jval.2026.02.004_bib30","series-title":"China Guidelines for Pharmacoeconomic Evaluations (Chinese-English Version)","author":"Liu","year":"2020"},{"issue":"12","key":"10.1016\/j.jval.2026.02.004_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40273-022-01196-w","article-title":"Cost effectiveness of adding pembrolizumab to platinum and fluoropyrimidine-based chemotherapy as first-line treatment for advanced esophageal cancer: a US healthcare Payer\u2019s perspective","volume":"40","author":"Qu","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-022-02516-9","article-title":"A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.jval.2026.02.004_bib35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clinthera.2012.01.012","article-title":"Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context","volume":"34","author":"Wu","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2026.02.004_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920916000","article-title":"Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer","volume":"12","author":"Wu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.jval.2026.02.004_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-094804","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jval.2026.02.004_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jrsm.1085","article-title":"Assessing key assumptions of network meta-analysis: a review of methods","volume":"4","author":"Donegan","year":"2013","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.jval.2026.02.004_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jval.2026.02.004_bib41","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2026.02.004_bib42","series-title":"NICE DSU Technical Support Document 21: Flexible Methods for Survival Analysis","author":"Rutherford","year":"2020"},{"issue":"2","key":"10.1016\/j.jval.2026.02.004_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14737167.2023.2291155","article-title":"Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore","volume":"24","author":"Cher","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib44","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12913-023-09728-6","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.jval.2026.02.004_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States","volume":"27","author":"Mudumba","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s12913-025-12876-6","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience","volume":"25","author":"Yaghoubi","year":"2025","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.jval.2026.02.004_bib47","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10198-023-01617-3","article-title":"Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and\/or metastatic breast cancer in Finland","volume":"25","author":"Paulissen","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2026.02.004_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12874-025-02480-x","article-title":"Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma","volume":"25","author":"Fawsitt","year":"2025","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.jval.2026.02.004_bib49","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1007\/s12325-025-03144-4","article-title":"Pembrolizumab with carboplatin and paclitaxel versus alternative systemic treatments recommended for the first-line treatment of recurrent\/metastatic head and neck cancer: an indirect treatment comparison","volume":"42","author":"Dzienis","year":"2025","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.jval.2026.02.004_bib50","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2026.02.004_bib51","series-title":"NICE Decision Support Unit Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"issue":"3","key":"10.1016\/j.jval.2026.02.004_bib52","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo","year":"2020","journal-title":"J R Stat Soc A"},{"issue":"16","key":"10.1016\/j.jval.2026.02.004_bib53","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"Bach","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jval.2026.02.004_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.02.004_bib55","author":"Monnereau"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:20:14Z","timestamp":1785453614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1098301526000768"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.02.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}